Session date: 
05/25/2018 - 8:00am to 9:00am

Jacksonville - 8:00 – 9:00 am

Mayo – Mayo 2-002N

Brooks - https://zoom.us/

If you are unable to attend in person, you can access the conference by webcast:

Internally: http://videoexchange.mayo.edu/category/Live+Events%3EFriday/22505032

Archive: http://videoexchange.mayo.edu/category/N%3ENeurology+Critical+Care+Course/21222962

Learning Objectives:

  • Review mechanism of action of novel oral anticoagulants (NOAC)/direct oral anticoagultants (DOAC)
  • Outline recent data about reversal of NOAC/DOAC with nonspecific antidotes in ICH
  • Define a recent trial using andexanet alpha for acute reversal for rivaroxaban and apixaban (FDA approved, label indication)

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s), please go here to review disclosures.

Presenter: 
Lauren Ng Tucker, M.D.
Where did the idea for the course originate?: 
Florida
Please login or register to take this course.
Where did the idea for the course originate?: 
Florida